These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10852664)

  • 1. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations.
    Mancini GB
    Clin Invest Med; 2000 Apr; 23(2):144-61. PubMed ID: 10852664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic antioxidant use and changes in endothelial dysfunction: a review of clinical investigations.
    Aminbakhsh A; Mancini J
    Can J Cardiol; 1999 Aug; 15(8):895-903. PubMed ID: 10446437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction in human disease.
    Drexler H; Hornig B
    J Mol Cell Cardiol; 1999 Jan; 31(1):51-60. PubMed ID: 10072715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications.
    Zeiher AM; Schächinger V
    Z Kardiol; 1994; 83 Suppl 4():7-14. PubMed ID: 7856284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
    Nawarskas JJ; Spinler SA
    Pharmacotherapy; 1998; 18(5):1041-52. PubMed ID: 9758314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ; Gums JG
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function.
    Pepine CJ
    J Am Coll Cardiol; 1996 Apr; 27(5):1048-52. PubMed ID: 8609320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for ACE inhibition as an anti-ischaemic therapy.
    Pepine CJ
    Eur Heart J; 1998 Jul; 19 Suppl G():G34-40. PubMed ID: 9717054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure.
    Sami M
    Can J Cardiol; 1999 May; 15 Suppl C():19C-23C. PubMed ID: 10380688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients.
    Tezcan H; Yavuz D; Toprak A; Akpinar I; Koç M; Deyneli O; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):119-23. PubMed ID: 12806595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.
    Donnelly R; Manning G
    J Renin Angiotensin Aldosterone Syst; 2007 Mar; 8(1):13-22. PubMed ID: 17487822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.